Ann: Update on Oculopharyngeal Muscular Dystrophy Program, page-63

Blane - this is for you:

””Benitec team endeavors to conduct several additional exploratory analyses prior to the initiation of the clinical study in order to potentially improve the biological efficacy of the compound via further optimization of the proprietary delivery method employedto dose the target tissues.””

There is nothing here about failure or challenges in the previous work on OPMD. To me it speaks to the future and NEW opportunities that have presented themselves in our labs. You may say word-smithing. I say Axovant would not accept that. They have angry and frustrated shareholders and would want the truth if there were scientific challenges or setbacks. And that would make Axovant look justified in losing the 12 million.